

**Date: 16th September, 2026**

To,

BSE Limited

Listing Department,

Phiroze Jeejeebhoy Towers,

Dalal Street - Fort,

Mumbai — 400 001.

Ref.: BSE Scrip Code - 539730

Subject: Outcome of Board Meeting Dated 16th September, 2026*Re: Allotment of 2,71,200 Equity Shares to Non-Promoter upon conversion of Warrants into Equity Shares*

Dear Sir,

This is to inform you that Board of Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on October 22, 2025, had allotted convertible warrants on preferential basis to Allottees on December 29, 2025.

Further, we would like to inform that the Warrant Holders have paid the balance of the consideration and have applied for exercising their rights for conversion of 90,400 warrants into 2,71,200 number of Equity Shares.

Consequently, the Board of Directors in its meeting held on September 16, 2026 has allotted 2,71,200 Equity Shares of face value Rs. 10/- each to the warrant holder as per following details:

Sr. No.	Name of Allottee	Category of Investor	Total number of convertible warrants allotted on December 29, 2025	Number of Equity Shares allotted upon conversion of Warrants on April 09, 2026 [#]	Number of Warrants Outstanding for Conversion
1	Alchemy Capital Management Pvt Ltd	Non-Promoter	24,000	54,000	6,000
	Alchemy Long Term Ventures Fund, Series 2	Non-Promoter	32,000	72,000	8,000
	Ajay Kumar Aggarwal	Non-Promoter	32,000	72,000	8,000
	Divya Aggarwal	Non-Promoter	8,000	7,200	5,600
	Swati Goel	Non-Promoter	8,000	12,000	4,000
	Sweta Chokhany	Non-Promoter	4,000	9,000	1,000
	Vartika Chokhany	Non-	4,000	9,000	1,000





		Promoter			
	Vivek Dhir	Non-Promoter	8,000	18,000	2,000
	Ceramet Consultants Private Limited	Non-Promoter	4,000	9,000	1,000
	Nav Ratan Bhaiya	Non-Promoter	4,000	9,000	1,000
	TOTAL		90400	271200	37600

Pursuant to the 1:2 Bonus Issue made by the Company, the entitlement attached to the outstanding warrants stands adjusted in the same proportion as the Bonus Issue, in accordance with the applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Accordingly, each outstanding warrant shall be entitled to the corresponding enhanced number of Equity Shares upon exercise, with the exercise consideration being adjusted correspondingly.

The allotment of the equity shares shall be made in dematerialized form and the equity shares so allotted shall rank pari passu with the existing Equity Shares of the Company in all respects.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular dated January 30, 2026 are enclosed as "**Annexure I**".

The meeting commenced at 06:00 p.m. and concluded at 08:00 p.m.

Kindly take the aforesaid information on your records.

Thanking you,

FOR FREDUN PHARMACEUTICALS LIMITED

FREDUN NARIMAN MEDHORA
MANAGING DIRECTOR
DIN NO.: 01745348

Encl. : Annexure I



**Annexure I****Information as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015****Issuance of Securities:**

Sr. No.	Particulars of Securities	Details of Securities
a)	Type of securities proposed to be issued	Equity Shares upon conversion of Warrants into Equity Shares of Rs. 10/- each.
b)	Type of issuance	Preferential Issue in accordance with Chapter V of the SEBI ICDR Regulations 2018 and other applicable law
c)	Total number of securities proposed to be issued or the total amount for which the securities will be issued	Allotment of 2,71,200 Fully Paid-Up Equity Shares.
In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):		
i.	Name of Investors	Mentioned in the Covering Letter above.
ii.	Post Allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles),	Warrants were allotted on December 29, 2025, carrying the right to subscribe to Equity Shares upon exercise of the option attached to each warrant, at an issue price of Rs. 1,250/- per warrant, of which Rs. 312.50/- per warrant, being 25% of the issue price, was payable upfront. Subsequently, pursuant to the 1:2 Bonus Issue made by the Company, the entitlement attached to the outstanding warrants was adjusted in accordance with the applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Accordingly, pursuant to such adjustment, 90,400 outstanding warrants were exercisable into 2,71,200 Equity Shares, i.e. three Equity Shares for each outstanding warrant, upon payment of the applicable balance consideration..
iii.	No. of Investors	10 (Ten)
iv.	in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	As the total consideration of the 90,400 Convertible Warrants is received, the Equity Shares are allotted pursuant to exercise of the conversion of Convertible Warrants.





v.	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not Applicable
----	--	----------------

